Jeroen Kortekaas received his PhD from the University of Utrecht, after completing his thesis on the “Vaccine potential of iron regulated outer membrane receptors of Neisseria meningitidis ”. In 2006, he joined the Central Veterinary Institute, which is now named Wageningen Bioveterinary Research (WBVR). His main responsibility at WBVR was to develop vaccines for the control of notifiable transboundary veterinary and zoonotic viral diseases. The first vaccine that was developed under his supervision can be used to control Classical swine fever virus (Flaviviridae, genus Pestivirus) and enables the Differentiation between Infected and Vaccinated Animals (DIVA). From 2007 until 2021, the research of his team focused on Rift Valley fever virus (RVFV) and other members of the order Bunyavirales, with an additional interest in zoonotic arboviruses of the families Togaviridae and Flaviviridae. He has (co)authored more than 70 publications in peer reviewed scientific journals and 6 patent applications. Apart from his involvement in vaccine development and fundamental studies on arboviruses, he was an ad hoc member of several Rift Valley fever expert panels of the World Organisation for Animal Health, the United Nations Food and Agriculture Organization (FAO), Health for Animals (International Federation for Animal Health Europe) and the Coalition for Epidemic Preparedness Initiative (CEPI). He was coordinator of two large, international projects, focused on the development of veterinary and human RVF vaccines. The latter LARISSA project ( https://www.larissa.online/) is funded by CEPI. In 2017, he became CSO of BunyaVax (www.bunyavax.com), a company that develops vaccines using proprietary platform technologies. In the same year, he was appointed special professor of the Laboratory of Virology of Wageningen University. He was also member of the Netherlands Commission on Genetic Modification (COGEM) and member of the board of the Virology Division of the Royal Dutch Society for Microbiology. In September 2021 he moved from the Netherlands to France, to take up the position of Research Director Transboundary and Emerging Diseases at Boehringer Ingelheim Animal Health (Saint Priest).